PR Newswire BiotechOriginal article
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
Phase 2ExalurenPositive
AI Analysis
Summary
Eloxx Pharmaceuticals announced the first patients have been dosed in the Phase 2b EXACT study of Exaluren for nonsense mutation Alport Syndrome, with topline data from the 16-week placebo-controlled portion expected mid-2027 and final readout by end of 2027.
Clinical Trial Data
Phase
2b
Patients
2
Outcome Details
First patients dosed in Phase 2b EXACT study
Importance:5/10
Sentiment:
0.50
Phase 2btrial initiationAlport Syndromenonsense mutationExaluren
Related Companies
Read the original article
Published by PR Newswire Biotech on September 11, 2026 11:30 AM